EMA accepts marketing authorisation application for avacopan

The European Medicines Agency (EMA) has accepted the conditional marketing authorisation application for avacopan in the treatment of patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Read more

4 Jan 2018 12:00 News